Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients

Study ID
NCT00134758

Study type
Interventional

Study phase
Phase 2/Phase 3

Study status
Unknown status

Trial Acronym

Trial Summary

Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.

More informations

Trial Starting Date

Oct 31,2004

Requirements

Gender All
Minimum age 18 Years
Maximum age 65 Years

Enrollement Limit